Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the EMA
Biosimilar infliximab alone could potentially save the NHS £89 million.
Sandoz has announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Applications for biosimilars to Humira (adalimumab) and Remicade (infliximab), both of which are used to treat immunological diseases. Today’s news comes shortly after two positive Committee for Medicinal Products for Human Use (CHMP) opinions for Sandoz biosimilars of etanercept and rituximab, reinforcing Sandoz’s immunology pipeline and the broader Novartis immunology portfolio.
Adalimumab and infliximab are the first and 5th most expensive medicines on the NHS by prescribing cost respectively,ii totalling a combined spend of approximately £594 million in 2015/16. The introduction of biosimilars for these medicines may contribute to a significant reduction in the NHS medicines bill, with biosimilar infliximab alone potentially contributing savings of £89 million. These savings offer the potential for reinvestment to improve patient care or access to future treatments.
Tim de Gavre, Country Head of Sandoz UK, said: “The filing acceptance of both adalimumab and infliximab biosimilar medicines by the EMA is a significant milestone for Sandoz. Biologics are an established class of medicines that have revolutionised treatment for patients with immunological diseases. If approved, biosimilar adalimumab and biosimilar infliximab may increase access to these important medicines, which currently on the NHS can be limited. Today’s news reinforces Sandoz’s leadership in the biosimilars field and strengthens our commitment to patient access and the research and development of biosimilar medicines.”
Sandoz is seeking approval of both medicines for use in all indications in line with their respective reference products. If approved, these medicines will be available for patients with conditions such as rheumatoid arthritis (RA) and inflammatory bowel disease, which affect approximately 400,000 and 240,000 patients in the UK respectively.
The EMA submissions include analytical, preclinical and clinical data packages across quality, efficacy, and safety which demonstrate biosimilarity of the proposed biosimilar medicines to the respective reference medicines. The biosimilar adalimumab submission includes clinical data from pharmacokinetic pharmacodynamic (PK/PD) studies and a Phase III confirmatory efficacy and safety study in patients with moderate to severe chronic plaque psoriasis. The biosimilar infliximab submission includes clinical data from a PK/PD study and a Phase III confirmatory efficacy and safety study in rheumatoid arthritis.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance